Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Califf Factor: Commissioner Nominee's Role In IMPROVE-IT Gets Notice

Executive Summary

TIMI Study Group's Eugene Braunwald says Robert Califf, his co-chair on the IMPROVE-IT steering committee, 'worked very hard for nine-and-a-half years' on trial before leaving Duke to join FDA.

You may also be interested in...



IMPROVE-IT Study: Negative Panel Review Leaves FDA With Tough Choice

Approval of cardiovascular risk reduction claims for Merck's Zetia and Vytorin would fly in the face of advisory committee's recommendations, but rejection would mean the first outcomes study to show CV benefit for a non-statin, LDL-C-lowering agent did not provide substantial evidence.

Califf Nomination May Show Confidence In His Bipartisan Appeal

After seven months as deputy commissioner for medical products and tobacco, Robert Califf tapped to be FDA Commissioner.

US FDA Drugs Center Launches Clinical Trial Innovation Hub With Demonstration Projects

CDER’s Center for Clinical Trial Innovation (C3TI) will support innovative clinical trial approaches designed to improve the quality and efficiency of drug development and regulatory decision-making. The initiative includes demonstration projects on Bayesian analyses, selective safety data collection and point-of-care trials.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS057347

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel